Edmund Tai, MD
Anatomic Pathology & Clinical Pathology · Mountain View, CANPI 1487669933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,570 of the $159,984 with a category attached, or 63.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 79.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $35,549 and has fallen 62.4% since, to $13,355 in 2025. Among anatomic pathology & clinical pathology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $663.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$128K
- AstraZeneca$15K
- Novartis$7K
- Genentech USA, Inc.$3K
- Boehringer Ingelheim$3K
- Pfizer$2K
- plus $3K from 20 others
Across 2 payments — averaging $8692.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
What the payments were for
- Consulting fees$30,42319%
- Speaking & faculty fees$101,57063%
- Travel & lodging$23,16914%
- Food & beverage$4,4543%
- Education$3690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 119 | $127,765 |
| AstraZeneca | 41 | $14,595 |
| Novartis | 6 | $6,515 |
| Genentech USA, Inc. | 6 | $3,039 |
| Boehringer Ingelheim | 1 | $2,670 |
| Pfizer | 32 | $1,905 |
| GSK | 3 | $1,883 |
| Bayer | 1 | $900 |
| Daiichi Sankyo Inc. | 5 | $124 |
| Johnson & Johnson(2 entities) | 4 | $118 |
| Secura Bio, Inc. | 3 | $82 |
| Merck | 2 | $43 |
| AbbVie | 2 | $42 |
| Gilead | 2 | $37 |
| Genentech, Inc. | 2 | $35 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Clovis Oncology, Inc. | 2 | $27 |
| Coherus Oncology, Inc. | 1 | $26 |
| Array Biopharma Inc | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$159,984 in reported general payments places this provider in the 95th percentile of 814 anatomic pathology & clinical pathology providers in California.
See all anatomic pathology & clinical pathology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 25 | $319,334 |
| XareltoRivaroxaban | 36 | $45,373 |
| EliquisApixaban | 48 | $44,996 |
| Megestrol Acetate | 16 | $946 |
| Hydroxyurea | 15 | $926 |
| Anastrozole | 61 | $855 |
| Dexamethasone | 38 | $780 |
| Acyclovir | 44 | $769 |
| Folic Acid | 13 | $286 |
| Potassium Chloride | 18 | $246 |
| Lorazepam | 13 | $86 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $118 | $45,37336 claims |
| PfizerEliquis | $1,905 | $44,99648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 814 anatomic pathology & clinical pathology providers in California.
Other anatomic pathology & clinical pathology in Mountain View
- Serge AlexanianLos Angeles$3.2M
- Brian ConeLos Angeles$519K
- John BlausteinSanta Barbara$464K
- Henry TsaiHuntington Beach$414K
- Stewart ComerSanta Barbara$313K
- Eric VailWest Hollywood$298K
- Hua ShanStanford$295K
- Miriam Blochla Jolla$252K
- Michael LewisLos Angeles$220K
- Dawn EllersonSan Luis Obispo$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.